Existing investors Lilly Asia Ventures and SBCVC returned for the multiomics product developer's latest round, in which it raised nearly $100m.
Germany-headquartered cellular technology developer Singleron Biotechnologies has closed a series B round sized at almost $100m that included investment vehicles for pharmaceutical firm Eli Lilly and internet and telecommunications group SoftBank.
Lilly Asia Ventures and SBCVC were joined in the round by Lake Bleu Capital, Firstred Capital, MSA Capital, Sherpa Healthcare Partners, Arch Venture Partners, CDG Capital, CDH Investments, Superstring Capital and 3W Partners.
Singleron provides single-cell multiomics products such as laboratory instruments, microfluidic systems, reagents, software and database platforms…
